The stock of Titan Pharmaceuticals, Inc. (NASDAQ:TTNP) is a huge mover today! About 85,749 shares traded hands. Titan Pharmaceuticals, Inc. (NASDAQ:TTNP) has risen 65.08% since March 9, 2016 and is uptrending. It has outperformed by 57.67% the S&P500.
The move comes after 8 months negative chart setup for the $118.98M company. It was reported on Oct, 12 by Barchart.com. We have $4.90 PT which if reached, will make NASDAQ:TTNP worth $16.66 million less.
Analysts await Titan Pharmaceuticals, Inc. (NASDAQ:TTNP) to report earnings on November, 21. They expect $-0.11 earnings per share, down 22.22% or $0.02 from last year’s $-0.09 per share. After $0.55 actual earnings per share reported by Titan Pharmaceuticals, Inc. for the previous quarter, Wall Street now forecasts -120.00% negative EPS growth.
According to Zacks Investment Research, “Titan Pharmaceuticals, Inc. is a biopharmaceutical company developing proprietary therapeutics for the treatment of central nervous system disorders, cancer, and other serious and life threatening diseases. In the central nervous system arena, the company is developing iloperidone, which is clinical testing for schizophrenia through a licensing and development agreement with Novartis Pharma AG. Novartis has tradenamed the product Zomaril.”
More news for Titan Pharmaceuticals, Inc. (NASDAQ:TTNP) were recently published by: Seekingalpha.com, which released: “Titan Pharmaceuticals: What To Look For After Probuphine Approval” on May 27, 2016. Quotes.Wsj.com‘s article titled: “News Titan Pharmaceuticals Inc.TTNP” and published on February 13, 2011 is yet another important article.
TTNP Company Profile
Titan Pharmaceuticals, Inc. (Titan), incorporated on February 7, 1992, is a specialty pharmaceutical company. The Firm is engaged in developing therapeutics for the treatment of medical disorders. The Company’s segment is engaged in the development of pharmaceutical products. The Company’s product development programs utilize its long-term drug delivery platform, ProNeura. The Company’s drug candidate, Probuphine, is being developed for the long-term maintenance treatment of opioid dependence. Titan’s ProNeura continuous drug delivery system consists of a small, solid rod made from a mixture of ethylene-vinyl acetate (EVA) and a drug substance. The Firm focuses on developing two product development programs, the first one with a ropinirole implant for the treatment of Parkinson’s disease (PD) and the second one with a Triiodothyronine (T3) implant for the treatment of hypothyroidism. The Firm is engaged in the development of Probuphine for the maintenance treatment of opioid dependence. Probuphine utilizes ProNeura, Titan’s long-term drug delivery platform. Upon subdermal insertion in a patient, Probuphine is designed to release medication and maintains an around the clock blood level of the drug buprenorphine, an approved agent for the treatment of opioid dependence. Probuphine is in Phase III clinical study stage.
Receive News & Ratings Via Email - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings with our FREE daily email newsletter.